Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study entitled Community-Centered Interventions for Improved Vaccine Uptake for COVID-19 (CIVIC): Getting to Yes, Michigan!, is designed to increase vaccine uptake among populations that experience COVID-19 related disparities. The investigators will focus on the four counties within Michigan where a disproportionate burden of COVID-19 is within African Americans and Latinx communities, i.e., Wayne, Genesee, Kent and Washtenaw Counties. Using a community-based participatory research (CBPR) approach, CIVIC will leverage: its long term relationships with the communities involved, an established CBPR Steering Committee developed and the knowledge gained as a Community Engagement Alliance (CEAL) grant recipient, the resources and networks of the University of Michigan CTSA (MICHR), and the expertise of our academic partners to identify and understand factors that contribute to COVID-19 vaccine hesitancy in African Americans and Latinx communities in Michigan. The investigators will develop and test interventions based on community-centered approaches to achieve a primary goal of increased vaccine uptake.
The investigators will achieve this goal with the following aims:
Full description
Like many states across the country, COVID-19 cases and deaths have impacted communities of color in Michigan at disproportionately higher rates than whites. A staggering reality is that while African Americans represent only 13.6% of Michigan's population, they represent 40% of the deaths from COVID-19.
Preliminary data from the state reveal that these disparities will likely worsen due to significant hesitancy, fear, mistrust and misinformation regarding the COVID-19 vaccine if nothing is done to change current trends.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Eligibility inclusion criteria:
Exclusion criteria:
No specific racial, ethnic, nor sex/gender group is excluded.
Primary purpose
Allocation
Interventional model
Masking
700 participants in 2 patient groups
Loading...
Central trial contact
Ken Resnicow, Ph.D.; Emerson Delacroix, M.A.C.P.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal